Don’t miss the latest developments in business and finance.

Zydus Cadila receives USFDA approval to market Midodrine Hydrochloride Tablets

Image
Capital Market
Last Updated : Sep 03 2020 | 11:50 AM IST
Zydus Cadila received final approval from the USFDA to market Midodrine Hydrochloride Tablets (US RLD- ProAmatine Tablets) in the strengths of 2.5 mg, 5 mg, and 10 mg.

The drug is used for certain patients who have symptoms of low blood pressure when standing. This condition is also known as orthostatic hypotension. The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.

The group now has 298 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Sep 03 2020 | 11:23 AM IST

Next Story